UPDATE: On Wednesday, 15 August 2018, WHO Director-General, Dr Tedros Adhanom Ghebreyesus provided a response to the open letter on the Roadmap on Access to Medicines and Vaccines 2019-2023. The Director-General’s response can be found here: WHO DG letter to… Continue Reading
Update: the NIH has rejected our request for expedited processing of the FOIA, on the grounds that KEI did not demonstrate “that there exists an urgency to inform the public” about the costs of the NIH CAR T or mesothelin… Continue Reading
In June 2018, the European Union (EU) delivered the following statement on Intellectual Property and the Public Interest at the WTO TRIPS Council. The EU voiced a specific concern over a reference in the WTO submission by China and South… Continue Reading
More on 1498 here: https://www.keionline.org/cl/28usc1498 There is a discussion of compensation under 28 USC §1498 in Remuneration Guidelines for Non-Voluntary Use of a Patent on Medical Technologies. UNDP and World Health Organization. 2005 (pages 18-21 in the UNDP edition, and… Continue Reading
1997 James Love, Call for More Reliable Costs Data on Clinical Trials, The Marketletter, January 13, 1997. 2017 James Love, Orphan Drugs Designations and Approvals have Something to Say about Risks, Bill of Health, September 25, 2017. James Love, What… Continue Reading
Orphan Drug R&D Costs
The Managers Amendment for the “Tax Cuts and Jobs Act” is available on the Senate Finance web page here: https://www.finance.senate.gov/imo/media/doc/11.20.17%20Tax%20Cuts%20and%20Jobs%20Act.pdf I was looking over the Orphan Drug Tax Credit (ODTC) language. The earlier Senate Finance proposal was a more complex… Continue Reading
This was delivered the afternoon on October 3, 2017.
Opening statement of Knowledge Ecology International – WIPO General Assembly 2017
Thank you, Mr. Vice President.
KEI notes the controversies around the world regarding the costs and benefits of intellectual property policies, including in particular extended terms of copyright protection in some countries, access to copyrighted works out of commerce and in teaching and research, and the role of patents in both promoting and discouraging innovation, and creating barriers to access medicine.
In 2012 the US Patent and Trademark Office (USPTO) published a study titled “Intellectual Property and the U.S. Economy: Industries in Focus” which estimated the number of jobs if various “IP intensive” industries. The study was immediately panned by critics for its broad definitions — grocery stores were the top “ip intensive industry” in the United States, but it became a source of go-to-statistics for every PhRMA and publisher lobby group pushing new privileges and subsidies. (Commentary here: /node/1432)
Notes on the Blur Banff proposal* KEI Research Note 2013:1 February 1, 2013 This is a brief note on the Blur/Banff proposal for a system of decentralized decision making and competitive intermediaries to provide money to support recorded music that… Continue Reading